Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?

Allergan has chalked up some flattering safety data for abicipar as it refines the eye drug’s manufacturing processes in preparation of an impending BLA filing. But whether or how much that matters is still up for debate.